Oh Ester S, Na Muzi, Rogers Connie J
Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, United States.
Center for Molecular Immunology and Infectious Disease, Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, United States.
Front Cardiovasc Med. 2021 Feb 17;8:640124. doi: 10.3389/fcvm.2021.640124. eCollection 2021.
Monocyte subsets in humans, i.e., classical (CM), intermediate (IM), and non-classical monocytes (NCM), are thought to differentially contribute to the pathogenesis of atherosclerosis, the leading cause of cardiovascular disease (CVD). However, the association between monocyte subsets and cardiometabolic disorders and CVD is not well-understood. Thus, the aim of the current systematic review and meta-analysis was to evaluate recent findings from clinical studies that examined the association between the distribution of monocyte subsets in subjects with cardiometabolic disorders and CVD compared to healthy controls. Articles were systematically searched in CINAHL, PubMed and Cochrane Library. Articles were independently screened and selected by two reviewers. Studies that reported the percentage of each monocyte subset were included in the systematic review and meta-analysis. For the meta-analysis, a random-effects model was used to generate pooled standardized mean differences (SMD) between subjects with cardiometabolic disorders and healthy controls. A total of 1,693 articles were screened and 27 studies were selected for qualitative analyses. Among them, six studies were included in the meta-analysis. In total, sample size ranged from 22 to 135 and mean or median age from 22 to 70 years old. We found studies that reported higher percentage and number of IM and/or NCM in subjects with cardiometabolic disorders (9 out of 13 studies) and in subjects with CVD (11 out of 15 studies) compared to healthy controls. In the meta-analysis, the percentage of CM was lower [SMD = -1.21; 95% CI (-1.92, -0.50); = 0.0009; = 91%] and the percentage of IM [SMD = 0.56; 95% CI (0.23, 0.88); = 0.0008; = 65%] and NCM [SMD = 1.39; 95% CI (0.59, 2.19); = 0.0007; = 93%] were higher in subjects with cardiometabolic disorders compared to healthy controls. Individuals with cardiometabolic disorders and CVD may have a higher percentage of IM and NCM than healthy controls. Future studies are needed to evaluate the cause and biological significance of this potential altered distribution of monocyte subsets.
人类的单核细胞亚群,即经典单核细胞(CM)、中间型单核细胞(IM)和非经典单核细胞(NCM),被认为在动脉粥样硬化(心血管疾病(CVD)的主要病因)的发病机制中发挥不同作用。然而,单核细胞亚群与心脏代谢紊乱及CVD之间的关联尚未完全明确。因此,本系统评价和荟萃分析的目的是评估近期临床研究的结果,这些研究探讨了心脏代谢紊乱和CVD患者与健康对照相比,单核细胞亚群分布的相关性。我们在CINAHL、PubMed和Cochrane图书馆系统检索了相关文章。由两名评审员独立筛选和选择文章。报告了各单核细胞亚群百分比的研究被纳入系统评价和荟萃分析。对于荟萃分析,采用随机效应模型生成心脏代谢紊乱患者与健康对照之间的合并标准化均数差(SMD)。共筛选了1693篇文章,选择了27项研究进行定性分析。其中,6项研究被纳入荟萃分析。样本量总计从22至135不等,平均或中位年龄从22至70岁。我们发现,与健康对照相比,有13项研究中的9项报告心脏代谢紊乱患者的IM和/或NCM百分比及数量更高,15项研究中的11项报告CVD患者的上述指标更高。在荟萃分析中,心脏代谢紊乱患者的CM百分比更低[SMD = -1.21;95%可信区间(-1.92,-0.50);P = 0.0009;I² = 91%],而IM[SMD = 0.56;95%可信区间(0.23,0.88);P = 0.0008;I² = 65%]和NCM[SMD = 1.39;95%可信区间(0.59,2.19);P = 0.0007;I² = 93%]百分比更高。心脏代谢紊乱和CVD患者的IM和NCM百分比可能高于健康对照。未来需要开展研究以评估这种潜在的单核细胞亚群分布改变的原因及生物学意义。